Clinical Trial: NCT05290155
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Information Provided By: | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Last Update Posted: | 2025-06-06 |
Study Overview
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting CD7 in patients with relapsed or refractory CD7 positive T-cell hematological maliganacies
Official Title
The Safety and Clinical Efficacy of Human CD7 CAR-T Cell Therapy for Patients With Relapsed/Refractory CD7 Positive T Cell Hematological Maliganacies
Conditions
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Intervention / Treatment
- Drug: anti-CD7 CAR-T cells
Other Study ID Numbers
- SHYSXY-202105-CD7-CART
Start Date (Actual)
2022-05-04
Primary Completion Date (Actual)
2024-08-01
Study Completion Date (Actual)
2025-05-01
Enrollment (Actual)
14
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Information Provided By: | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Last Update Posted: | 2025-06-06 |
Study Overview
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment targeting CD7 in patients with relapsed or refractory CD7 positive T-cell hematological maliganacies
Official Title
The Safety and Clinical Efficacy of Human CD7 CAR-T Cell Therapy for Patients With Relapsed/Refractory CD7 Positive T Cell Hematological Maliganacies
Conditions
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Intervention / Treatment
- Drug: anti-CD7 CAR-T cells
Other Study ID Numbers
- SHYSXY-202105-CD7-CART
Start Date (Actual)
2022-05-04
Primary Completion Date (Actual)
2024-08-01
Study Completion Date (Actual)
2025-05-01
Enrollment (Actual)
14
Study Type
Interventional
Phase
Phase 1